270 related articles for article (PubMed ID: 21781149)
1. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Fogari R; Mugellini A; Destro M; Corradi L; Lazzari P; Zoppi A; Preti P; Derosa G
Diabet Med; 2012 Jan; 29(1):24-31. PubMed ID: 21781149
[TBL] [Abstract][Full Text] [Related]
2. [Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
Shibasaki Y; Nishiue T; Masaki H; Matsubara H; Iwasaka T
Nihon Rinsho; 2002 Oct; 60(10):1992-8. PubMed ID: 12397697
[TBL] [Abstract][Full Text] [Related]
3. Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
Iwashima Y; Okada M; Haneda M; Yoshida T
Diabetes Res Clin Pract; 2006 Oct; 74(1):8-14. PubMed ID: 16720057
[TBL] [Abstract][Full Text] [Related]
4. [Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients].
Oliván J; Moreno R; Hoyos M; Ramos E; Rodríguez A; Pizarro JL; Justo E; Pérez Cano R
An Med Interna; 1996 Nov; 13(11):531-6. PubMed ID: 9019211
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
6. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
7. Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension.
Beltman FW; Heesen WF; Smit AJ; May JF; de Graeff PA; Havinga TK; Schuurman FH; van der Veur E; Lie KI; Meyboom-de Jong B
Blood Press; 1998 May; 7(2):109-17. PubMed ID: 9657538
[TBL] [Abstract][Full Text] [Related]
8. Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.
Derosa G; Mugellini A; Querci F; Franzetti I; Pesce RM; D'Angelo A; Maffioli P
Sci Rep; 2015 Aug; 5():12603. PubMed ID: 26243165
[TBL] [Abstract][Full Text] [Related]
9. [Effect of cilazapril therapy on diastolic filling and left ventricular hypertrophy in patients with arterial hypertension].
De Simone R; Irace L; Perna B; Caruso C; Guida M; Iacono A
Minerva Cardioangiol; 1993 May; 41(5):205-9. PubMed ID: 8355860
[TBL] [Abstract][Full Text] [Related]
10. Losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction in hypertensives, but does not affect diastolic cardiac function.
Zakynthinos E; Pierutsakos Ch; Konstantinidis K; Zakynthinos S; Papadogiannis D
Angiology; 2004; 55(6):669-78. PubMed ID: 15547653
[TBL] [Abstract][Full Text] [Related]
11. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy.
Galderisi M; Cicala S; De Simone L; Caso P; Petrocelli A; Pietropaolo L; Celentano A; Mininni N; de Divitiis O
Ital Heart J; 2001 Sep; 2(9):677-84. PubMed ID: 11666096
[TBL] [Abstract][Full Text] [Related]
12. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
Rakić D; Rumboldt Z; Bagatin J; Polić S
Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
[TBL] [Abstract][Full Text] [Related]
13. Improvement of diastolic function after regression of left ventricular hypertrophy.
Teniente-Valente R; Solorio S; Vargas-Salado E; Aguirre-Vázquez C; Hernández-González MA; Olvera-Lopez JA; Rodríguez-Mariscal L; Luna-Ruiz MA; Guillén Contreras JM; Murillo Ortiz BO
Arch Cardiol Mex; 2008; 78(4):392-9. PubMed ID: 19205547
[TBL] [Abstract][Full Text] [Related]
14. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
[TBL] [Abstract][Full Text] [Related]
15. Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Palmieri V; Okin PM; Bella JN; Wachtell K; Oikarinen L; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2006 Oct; 24(10):2079-84. PubMed ID: 16957569
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan.
Yu G; Liang X; Xie X; Yang T; Sun M; Zhao S
Chin Med J (Engl); 2002 Sep; 115(9):1287-91. PubMed ID: 12411096
[TBL] [Abstract][Full Text] [Related]
17. Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial.
Kloner RA; Neutel J; Roth EM; Weiss R; Weinberger MH; Thakker KM; Schwartz B; Shi H; Gregg AM;
Ann Pharmacother; 2008 Nov; 42(11):1552-62. PubMed ID: 18827176
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
Wachtell K; Palmieri V; Gerdts E; Bella JN; Aurigemma GP; Papademetriou V; Dahlöf B; Aalto T; Ibsen H; Rokkedal JE; Devereux RB
Am J Cardiol; 2010 Oct; 106(7):999-1005. PubMed ID: 20854964
[TBL] [Abstract][Full Text] [Related]
19. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
[TBL] [Abstract][Full Text] [Related]
20. EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics.
Hassanein A; Desai A; Verma A; Oparil S; Izzo J; Rocha R; Hilkert R; Seifu Y; Pitt B; Solomon S
Ther Adv Cardiovasc Dis; 2009 Dec; 3(6):429-39. PubMed ID: 19638366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
